Reversible acetylation of chromatin: Implication in regulation of gene expression, disease and therapeutics

Biotechnology Journal

Volumn 4, Issue 3, 2009, Pages 375-390

  Selvi, B Ruthrotha ^a   Kundu, Tapas K ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Chromatin; Disease; Therapeutics

Indexed keywords

BIOLOGICAL ACTIVITIES; CARDIAC HYPERTROPHIES; CELLULAR FUNCTIONS; CHROMATIN; EUKARYOTIC GENOMES; HDAC INHIBITORS; HISTONE DEACETYLASES; NEURODEGENERATIVE DISORDERS; NEW CLASS; POST-TRANSLATIONAL MODIFICATIONS; REVERSIBLE ACETYLATIONS; SMALL MOLECULES; TEMPLATED; THERAPEUTIC EFFICACIES; THERAPEUTIC STRATEGIES; THERAPEUTICS;

ACETYLATION; BIOACTIVITY; CATALYSTS; COMPRESSED AIR MOTORS; DNA; ENZYMES; GENE EXPRESSION; LIGANDS; NUCLEIC ACIDS; RNA;

CHROMOSOMES;

ANACARDIC ACID; CURCUMIN; GARCINOL; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; LTK 14; N (4 CHLORO 3 TRIFLUOROMETHYLPHENYL) 2 ETHOXYBENZAMIDE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ASTHMA; CHROMATIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG STRUCTURE; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; VIRUS PATHOGENESIS;

ACETYLATION; ANIMALS; ASTHMA; CHROMATIN; DIABETES MELLITUS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HEART DISEASES; HISTONES; HUMANS; MALARIA; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRUS DISEASES;

EUKARYOTA;

EID: 64549139803     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200900032     Document Type: Review

References (58)

1. Luger, K., Rechsteiner, T. J., Flaus, A. J., Waye, M. M., Richmond, T. J., Characterization of nucleosome core particles containing histone proteins made in bacteria. J. Mol. Biol. 1997, 272, 301-311.
2. Tumbar, T., Sudlow, G., Belmont, A.S., Large-scale chromatin unfolding and remodeling induced by VP16 acidic activation domain. J. Cell Biol. 1999, 145, 1341-1353.
3. Bhaumik, S. R., Smith, E., Shilatifard, A., Covalent modifications of histones during development and disease pathogenesis. Nat. Struct. Mol. Biol. 2007, 14, 1008-1016.
4. Roth, S.Y., Denu, J. M., Allis, C. D., Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70, 81-120.
5. Grant, P. A., Berger, S. L., Histone acetyltransferase complexes. Semin. Cell. Dev. Biol. 1999, 10, 169-177.
6. Xu, W., Edmondson, D.G., Roth, S.Y., Mammalian GCN5 and PrCAF acetyltransferases have homologous amino-terminal domains important for recognition of nucleosomal substrates. Mol. Cell. Biol. 1998, 18, 5659-5669.
7. Yang, X. J., Ogryzko, V., Nishikawa, J., Howard, B. H., Nakatani, Y., A p300rCBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382, 319-324.
8. Rouaux, C., Loeffler, J. P., Boutillier, A. L., Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem. Pharmacol. 2004, 68, 1157-1164.
9. Ma, K., Chan, J. K., Zhu, G., Wu, Z., Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation. Mol. Cell. Biol. 2005, 25, 3575-3582.
10. Avvakumov N, Côté J., The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007, 26, 5395-5407.
11. Doyon, Y., Selleck, W., Lane, W. S., Tan, S., Côté J., Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol. Cell. Biol. 2004, 24, 1884-1896.
12. Benson, L. J., Phillips, J. A., Gu, Y., Parthun, M. R. et al., Properties of the type B histone acetyltransferase Hat1: H4 tail interaction, site preference, and involvement in DNA repair. J. Biol. Chem. 2007, 282, 836-842.
13. Wang, L., Tang, Y., Cole, P. A., Marmorstein, R., Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: Implications for histone acetyltransferase evolution and function. Curr. Opin. Struct. Biol. 2008, 18, 741-747.
14. Daniel, J. A., Torok, M. S., Sun, Z.W., Schieltz, D. et al., Deubiquitination of histone H2B by a yeast acetyltransferase complex regulates Transcription. J. Biol. Chem. 2004, 279, 1867-1871.
15. Galbiati, L., Mendoza-Maldonado, R., Gutierrez, M. L., Giacca, M., Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 2005, 4, 930-939.
16. Linares, L. K., Kiernan, R., Triboulet, R., Chable-Bessia, C. et al., Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 2007, 9, 331-338.
17. Grimaldi, B., Coiro, P., Flietici, P., Berge, E. et al., The Neurospora crassa White Collar-1 dependent blue light response requires acetylation of histone H3 lysine 14 by NGF-1. Mol. Biol. Cell 2006, 17, 4576-4583.
18. Fan, Q., An, L., Cui, L., PfADA2, a Plasmodium falciparum homologue of the transcriptional coactivator ADA2 and its in vivo association with the histone acetyltransferase PfGCN5. Gene 2004, 336, 251-261.
19. Hettmann, C., Soldati, D., Cloning and analysis of a Toxoplasma gondii histone acetyltransferase: A novel chromatin remodelling factor in Apicomplexan parasites. Nucleic Acids Res. 1999, 27, 4344-4352.
20. Smith, A.T., Tucker-Samaras, S.D., Fairlamb, A. H., Sullivan, W. J. Jr., MYST family histone acetyltransferases in the protozoan parasite Toxoplasma gondii. Eukaryot. Cell 2005, 4, 2057-2065.
21. Bhatti, M. M., Livingston, M., Mullapudi, N., Sullivan, W. J. Jr., Pair of unusual GCN5 histone acetyltransferases and ADA2 homologues in the protozoan parasite Toxoplasma gondii. Eukaryot. Cell 2006, 5, 62-76.
22. Hildmann, C., Riester, D., Schwienhorst, A., Histone deacetylases - An important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 2007, 75, 487-497.
23. Merrick, C. J., Duraisingh, M.T., Plasmodium falciparum Sir2: An unusual sirtuin with dual histone deacetylase and ADPribosyltransferase activity. Eukaryot. Cell 2007, 6, 2081-2091.
24. Wiley, E. A., Ohba, R., Yao, M. C., Allis, C. D., Developmentally regulated rpd3p homolog specific to the transcriptionally active macronucleus of vegetative Tetrahymena thermophila. Mol. Cell. Biol. 2000, 20, 8319-8328.
25. Brandtner, E. M., Lechner, T., Loidl, P., Lusser, A., Molecular identification of PpHDAC1, the first histone deacetylase from the slime mold Physarum polycephalum. Cell Biol. Int. 2002, 26, 783-789.
26. Berger, S. L, The complex language of chromatin regulation during transcription. Nature 2007, 447, 407-412.
27. Li, B., Carey, M., Workman, J. L., The role of chromatin during transcription. Cell 2007, 128, 707-719.
28. Paule, M. R., White, R. J., Survey and summary:Transcription by RNA polymerases I and III. Nucleic Acids Res. 2000, 28, 1283-1298.
29. Troke, P. J., Kindle, K.B., Collins, H. M., Heery, D. M., MOZ fusion proteins in acute myeloid leukaemia. Biochem. Soc. Symp. 2006, 73, 23-39.
30. Doyon, Y., Cayrou, C., Ullah, M., Côté V. et al., ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 2006, 21, 51-64.
31. Bai, X., Wu, L., Liang, T., Liu, Z. et al., Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134, 83-91.
32. Gray, S. G., De Meyts P., Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev. 2005, 21, 416-433.
33. Barnes, P. J., Adcock, I. M., Ito, K., Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur. Respir. J. 2005, 25, 552-563.
34. Quivy, V., De Walque, S., Van Lint, C., Chromatin-associated regulation of HIV-1 transcription: Implications for the development of therapeutic strategies, in: Kundu, T. K., Dasgupta, D. (Eds), Chromatin and Disease, vol. 41, Springer, Berlin 2007, pp. 371-396.
35. Saha, R. N., Pahan, K., HATs and HDACs in neurodegeneration: A tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006, 13, 539-550.
36. McKinsey, T. A., Olson, E. N., Cardiac histone acetylation - Therapeutic opportunities abound. Trends Genet. 2004, 20, 206-213.
37. Freitas-Junior, L. H., Hernandez-Rivas, R., Ralph, S. A., Montiel-Condado, D., et al., Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell 2005, 121, 25-36.
38. Cui, L., Miao, J., Cui, L., Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: Inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob. Agents Chemother. 2007, 51, 488-494.
39. Cui, L., Miao, J., Furuya, T., Fan, Q. et al., Histone acetyltransferase inhibitor anacardic acid causes changes in global gene expression during in vitro Plasmodium falciparum development. Eukaryot. Cell 2008, 7, 1200-1210.
40. Yoshida, M., Kijima, M., Akita, M., Beppu, T., Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
41. Balasubramanyam, K., Swaminathan, V., Ranganathan, A., Kundu, T. K., Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 2003, 278, 19134-19140.
42. Balasubramanyam, K., Varier, R. A., Altaf, M., Swaminathan, V. et al., Curcumin, a novel p300/CREB-binding proteinspecific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163-51171.
43. Balasubramanyam, K., Altaf, M., Varier, R.A., Swaminathan, V. et al., Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279, 33716-33726.
44. Mantelingu, K., Reddy, B. A., Swaminathan, V., Kishore, A.H. et al., Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem. Biol. 2007, 14, 645-657.
45. Lau, O.D., Kundu, T. K., Soccio, R. E., Ait-Si-Ali, S. et al., HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 2000, 5, 589-595.
46. Liu, X., Wang, L., Zhao, K., Thompson, P. R. et al., The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008, 451, 846-850.
47. Cole, P.A., Chemical probes for histone-modifying enzymes. Nat. Chem. Biol. 2008, 4, 590-597.
48. Sbardella, G., Castellano, S., Vicidomini, C., Rotili, D. et al., Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg. Med. Chem. Lett. 2008, 18, 2788-2792.
49. Buczek-Thomas, J. A., Hsia, E., Rich, C. B., Foster, J. A., Nugent, M. A., Inhibition of histone acetyltransferase by glycosaminoglycans. J. Cell. Biochem. 2008, 105, 108-120.
50. Souto, J. A., Conte, M., Alvarez, R., Nebbioso, A. et al., Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. ChemMedChem. 2008, 3, 1435-1442.
51. Mantelingu, K., Kishore, A. H., Balasubramanyam, K., Kumar, G.V. et al., Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: Probed by surface-enhanced Raman spectroscopy. J. Phys. Chem. B 2007, 111, 4527-4534.
52. Selvi, B. R., Jagadeesan, D., Suma, B. S., Nagashankar, G. et al., Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: Delivery of membrane-impermeable molecule to modulate gene expression in vivo. Nano Lett. 2008, 8, 3182-3188.
53. Sankar, N., Baluchamy, S., Kadeppagari, R. K., Singhal, G. et al., p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008, 27, 5717-5728.
54. Wang, X., Cheung, H.W., Chun, A. C., Jin, D. Y., Wong, Y. C., Mitotic checkpoint defects in human cancers and their implications to chemotherapy. Front. Biosci. 2008, 13, 2103-2114.
55. Khan, O., La Thangue, N. B., Drug insight: Histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 2008, 5, 714-726.
56. Dokmanovic, M., Clarke, C., Marks, P.A., Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
57. Biel, M., Kretsovali, A., Karatzali, E., Papamatheakis, J., Giannis, A., Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew. Chem. Int. Ed. Engl. 2004, 43, 3974-3976.
58. Stimson, L., Rowlands, M. G., Newbatt, Y. M., Smith, N. F. et al., Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 2005, 4, 1521-1532.